Eli Lilly launches blockbuster weight loss drug Mounjaro in India

Eli Lilly’s Weight-Loss Drug: A Game-Changer for India’s Battle Against Obesity

Obesity has emerged as a significant public health challenge in India, with the country witnessing a rapid rise in overweight and obese populations over the past two decades. According to the National Family Health Survey (NFHS-5), nearly 23% of women and 22% of men in India are overweight or obese, a sharp increase from previous years..Enter Eli Lilly in India, Its a global pharmaceutical giant, whose weight-loss drugs are making waves worldwide and could soon play a pivotal role in India’s fight against obesity.

Eli Lilly Launches Weight-Loss Drug Mounjaro Pricing and Dosage

Eli Lilly has priced Mounjaro competitively for the Indian market, making it relatively more affordable compared to its cost in the U.S. The drug is available in two strengths:

• 2.5 mg vial: Priced at Rs 3,500

• 5 mg vial: Priced at Rs 4,375

Mounjaro is typically administered once a week, and the monthly cost of therapy would range between Rs 14,000 and Rs 17,500, depending on the dosage prescribed by the physician. This pricing is significantly lower than the average monthly cost of Mounjaro in the U.S., where it is priced at around $1,000-$1,000−1,200 (approximately Rs 86,000-1 lakh) per month. Eli Lilly’s pricing strategy for India reflects the company’s efforts to balance affordability with accessibility, ensuring that the drug reaches a broader patient base in a price-sensitive market.

About Eli Lilly and Company - A Legacy of Innovation in Healthcare

Eli Lilly and Company commonly referred to as Lilly. It is one of the world’s leading pharmaceutical corporations, renowned for its groundbreaking contributions to medicine and healthcare. Founded in 1876 by Colonel Eli Lilly, He was pharmaceutical chemist and Civil War veteran. Company has grown from a small Indianapolis-based operation to a global powerhouse with a presence in over 120 countries. Lilly’s mission has always been centered on improving patient outcomes through innovative treatments, and its portfolio spans a wide range of therapeutic areas, including diabetes, oncology, immunology, neuroscience, and more.

Global Presence and Impact

Lilly’s operations span the globe, with research facilities, manufacturing plants, and offices in numerous countries. The company employs over 39,000 people worldwide and invests heavily in research and development (R&D), spending approximately 25% of its revenue on R&D annually. This commitment to innovation has resulted in a robust pipeline of new drugs and therapies aimed at addressing unmet medical needs.